Antibiotic Cefepime: Lifesaver or Risk?

A comprehensive analysis of 110 randomized clinical trials, involving over 22,000 patients, has shed new light on safety concerns surrounding the antibiotic cefepime. This widely used drug, crucial for treating severe bacterial infections when the pathogen is unknown, was found to have a 94.4% probability of being associated with higher mortality odds than alternative treatments. This research revisits questions first raised nearly two decades ago.

The study indicated that for every 227 patients treated with cefepime instead of a comparison drug, one additional death might be associated. This signal for increased mortality was particularly pronounced when the analysis focused solely on published, peer-reviewed trials, where the probability rose to 98.6%. The increased risk appeared to be present in adults but not in children, prompting further investigation into potential biological differences or study-specific factors.

Special attention was given to patients with febrile neutropenia, a condition involving low white blood cell counts and fever, where the estimated probability of harm reached 96.1%. Higher doses of cefepime also showed a greater probability of harm. Potential explanations include the drug accumulating due to impaired kidney function, leading to toxic effects, especially in older or critically ill patients.

While the study identifies a concerning signal, experts caution that it is not definitive proof of causation. The absolute mortality rates were close (6.6% for cefepime versus 6.2% for comparators), and many factors influence survival in severely ill patients. However, the consistent signal across a large evidence base warrants further investigation.

Cefepime remains a valuable tool against life-threatening infections, particularly those caused by resistant bacteria. For an individual patient, the risk of undertreating a severe infection may outweigh the potential added risk suggested by this analysis. Future research should focus on understanding and mitigating this mortality signal, potentially through optimized dosing and improved monitoring, to ensure cefepime's continued safe and effective use.